Cargando…
Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review
Diffuse midline glioma (DMG) in children is a highly aggressive, malignant brain tumor that is fatal when relapsed. Wilms tumor 1 (WT1) is a high-priority antigen target for cancer immunotherapy. We hereby report on a pediatric patient who had DMG that regrew after chemoradiotherapy and underwent WT...
Autores principales: | Hashii, Yoshiko, Oka, Yoshihiro, Kagawa, Naoki, Hashimoto, Naoya, Saitou, Hiroyuki, Fukuya, Syogo, Kanegae, Mizuki, Ikejima, Sayaka, Oji, Yusuke, Ozono, Keiichi, Tsuboi, Akihiro, Sugiyama, Haruo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393264/ https://www.ncbi.nlm.nih.gov/pubmed/32793489 http://dx.doi.org/10.3389/fonc.2020.01188 |
Ejemplares similares
-
WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine
por: Alzaaqi, Shouq, et al.
Publicado: (2022) -
IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS’ TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS
por: Kagawa, Naoki, et al.
Publicado: (2019) -
WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023) -
A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
por: Tsuboi, Akihiro, et al.
Publicado: (2018) -
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)